Publications

A selection of our most recent published work:

June 2024 – ATTAINMENT: A phase Ib trial of MDX-124, a first-in-class annexin-A1 targeting antibody, alone and in combination with anti-cancer treatments, in patients with advanced solid tumors

Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024.

January 2024 – A therapeutic antibody targeting annexin-A1 inhibits cancer cell growth in vitro and in vivo

Published in high-impact Nature Portfolio journal Oncogene.

April 2022 – MDX-124, a novel annexin-A1 antibody, shows significant multi-faceted activity in preclinical models of various clinically challenging cancers

Presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting 2022.

January 2022 – Efficacy of MDX-124, a novel anti-annexin-A1 antibody, in preclinical models of pancreatic cancer

Presented at the ASCO Gastrointestinal Cancer Symposium 2022.

December 2021 – MDX-124, a novel annexin-A1 antibody, shows anti-tumor efficacy in several preclinical models of triple-negative breast cancer

Presented at the San Antonio Breast Cancer Symposium 2021.

April 2021 – MDX-124, a novel annexin-A1 antibody, induces an anti-tumor immune response and wide-ranging anti-cancer activity in multiple preclinical models

Presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting 2021.

March 2021 – HDX-MS for Epitope Characterization of a Therapeutic ANTIBODY Candidate on the Calcium-Binding Protein Annexin-A1

Published in the peer-reviewed open-access journal Antibodies.

June 2020 – Annexin-A1 as a Potential Therapeutic Target for Solid Tumors

Presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting 2020.

March 2020 – Annexin-A1: A New Immunomodulation / Checkpoint Pathway in Cancer

Presented at Transdisciplinary Cancer Interception: Leveraging Biology to Improve Prevention and Detection organised by Huntsman Cancer Institute at the University of Utah and Nature Reviews Cancer.